Tags

Type your tag names separated by a space and hit enter

Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects.
Intensive Care Med. 2001 Nov; 27(11):1825-9.IC

Abstract

OBJECTIVE

Impairment of haemostasis has been described with slowly degradable medium molecular weight hydroxyethyl starch (MMW-HES), whereas rapidly degradable MMW-HES is generally considered to have no important effects on blood coagulation. This study was undertaken to investigate the effects of a rapidly degradable MMW-HES plasma substitute on primary haemostasis and blood coagulation in human subjects.

DESIGN

Randomised, cross-over study.

SETTING

Research unit of a university hospital.

PARTICIPANTS

Nine healthy, adult male volunteers.

INTERVENTIONS

A 60-min intravenous infusion of 1 l HES 200/0.5/6 (HAES-steril 6%) or 4% albumin (control).

MEASUREMENT AND RESULTS

The infusion of HES resulted in decreased circulating levels of von Willebrand factor antigen (from 85+/-8% to 59+/-6% after HES vs from 80+/-7% to 69+/-8% after albumin, p<0.05) and ristocetin cofactor activity (from 93+/-4 to 67+/-4% after HES vs from 79+/-5 to 75+/-5% after albumin, p<0.01). This was associated with an impairment of in vitro platelet function as determined with the PFA-100 platelet function analyser (closure time with collagen/epinephrine from 120+/-7 to 159+/-14 s after HES vs from 121+/-7 to 137+/-10 s after albumin, p<0.05; with collagen/ADP from 88+/-3 to 116+/-9 s and from 103+/-4 to 114+/-7 s after HES and albumin, respectively, p=0.01).

CONCLUSIONS

The infusion of 1 l of HES 200/0.5/6 in healthy human subjects results in moderately decreased plasma levels of von Willebrand factor associated with impairment of platelet function.

Authors+Show Affiliations

Department of Intensive Care, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. e.dejonge@amc.uva.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11810130

Citation

de Jonge, E, et al. "Decreased Circulating Levels of Von Willebrand Factor After Intravenous Administration of a Rapidly Degradable Hydroxyethyl Starch (HES 200/0.5/6) in Healthy Human Subjects." Intensive Care Medicine, vol. 27, no. 11, 2001, pp. 1825-9.
de Jonge E, Levi M, Büller HR, et al. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med. 2001;27(11):1825-9.
de Jonge, E., Levi, M., Büller, H. R., Berends, F., & Kesecioglu, J. (2001). Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Medicine, 27(11), 1825-9.
de Jonge E, et al. Decreased Circulating Levels of Von Willebrand Factor After Intravenous Administration of a Rapidly Degradable Hydroxyethyl Starch (HES 200/0.5/6) in Healthy Human Subjects. Intensive Care Med. 2001;27(11):1825-9. PubMed PMID: 11810130.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. AU - de Jonge,E, AU - Levi,M, AU - Büller,H R, AU - Berends,F, AU - Kesecioglu,J, Y1 - 2001/09/26/ PY - 2000/10/27/received PY - 2001/08/21/accepted PY - 2002/1/26/pubmed PY - 2002/3/29/medline PY - 2002/1/26/entrez SP - 1825 EP - 9 JF - Intensive care medicine JO - Intensive Care Med VL - 27 IS - 11 N2 - OBJECTIVE: Impairment of haemostasis has been described with slowly degradable medium molecular weight hydroxyethyl starch (MMW-HES), whereas rapidly degradable MMW-HES is generally considered to have no important effects on blood coagulation. This study was undertaken to investigate the effects of a rapidly degradable MMW-HES plasma substitute on primary haemostasis and blood coagulation in human subjects. DESIGN: Randomised, cross-over study. SETTING: Research unit of a university hospital. PARTICIPANTS: Nine healthy, adult male volunteers. INTERVENTIONS: A 60-min intravenous infusion of 1 l HES 200/0.5/6 (HAES-steril 6%) or 4% albumin (control). MEASUREMENT AND RESULTS: The infusion of HES resulted in decreased circulating levels of von Willebrand factor antigen (from 85+/-8% to 59+/-6% after HES vs from 80+/-7% to 69+/-8% after albumin, p<0.05) and ristocetin cofactor activity (from 93+/-4 to 67+/-4% after HES vs from 79+/-5 to 75+/-5% after albumin, p<0.01). This was associated with an impairment of in vitro platelet function as determined with the PFA-100 platelet function analyser (closure time with collagen/epinephrine from 120+/-7 to 159+/-14 s after HES vs from 121+/-7 to 137+/-10 s after albumin, p<0.05; with collagen/ADP from 88+/-3 to 116+/-9 s and from 103+/-4 to 114+/-7 s after HES and albumin, respectively, p=0.01). CONCLUSIONS: The infusion of 1 l of HES 200/0.5/6 in healthy human subjects results in moderately decreased plasma levels of von Willebrand factor associated with impairment of platelet function. SN - 0342-4642 UR - https://www.unboundmedicine.com/medline/citation/11810130/Decreased_circulating_levels_of_von_Willebrand_factor_after_intravenous_administration_of_a_rapidly_degradable_hydroxyethyl_starch__HES_200/0_5/6__in_healthy_human_subjects_ L2 - https://dx.doi.org/10.1007/s001340101107 DB - PRIME DP - Unbound Medicine ER -